The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Tablets for heart failure patients.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Lupin receives US FDA approval for sacubitril and valsartan tablets: Our Bureau, Mumbai Friday, January 24, 2025, 15:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) announc ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

Chronic heart failure (CHF) is associated with frequent ... In patients with HF with reduced ejection fraction, HTN is treated differently in comparison to patients with HF with normal ejection ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

CVRx (NASDAQ:CVRX – Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, ...

Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CVRx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

Experts warn that this early stage of heart failure, classified as Stage B, often goes unnoticed but can lead to severe ...